Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 41

  • 1 291 clinical trials
  • 445 recruiting
  • 379 conditions
  • 29 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer332Asthma89Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV59Pulmonary arterial hypertension41COVID-1939Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Small cell lung cancer33Pneumonia32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza29Interstitial lung disease29Lung neoplasm malignant29Cystic fibrosis24Pulmonary hypertension24Conjunctivitis allergic23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 291 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 291 clinical trials

Non-small cell lung cancer stage III

Not yet recruiting

Fluorescence bronchoscopy to assess durvalumab-680LT distribution in unresectable stage III non‑small cell lung cancer patients after chemoradiation

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Universitair Medisch Centrum Groningen

Non-small cell lung cancer

Not yet recruiting

Phase 2 Study of Safety and Efficacy of PF-08634404 Alone or with Drug Combination in Adults with Early-Stage or Locally Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Pfizer Inc.

Sepsis+3

Not yet recruiting

Comparison of ampicillin plus gentamicin versus piperacillin/tazobactam for empirical treatment of hospitalized patients with community‑acquired infection

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Ampicillin Sodium
  • Sponsor:Rigshospitalet

Pulmonary hypertension

Not yet recruiting

Discontinuing vs Continuing Riociguat in Chronic Thromboembolic Pulmonary Hypertension Patients After Successful Balloon Pulmonary Angioplasty

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Riociguat
  • Sponsor:Assistance Publique Hopitaux De Paris

Tonsillitis

Not yet recruiting

Intravenous benzathine benzylpenicillin added to oral phenoxymethylpenicillin for relief in adults with acute tonsillitis, peritonsillar phlegmon and abscess

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:Sodium Chloride
  • Sponsor:Region Midtjylland

Malignant pleural effusion

Not yet recruiting

Study of Hyperthermic Intrathoracic Chemotherapy with Cisplatin and Pleurectomy versus Standard Care in Patients with Malignant Pleural Effusion

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Universita' Degli Studi Di Torino

Small cell lung cancer limited stage

Not yet recruiting

Durvalumab after chemoradiation for patients with limited‑stage small cell lung cancer: a randomized trial of high‑dose versus standard thoracic radiation

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Norwegian University Of Science And Technolology

Interstitial lung disease

Not yet recruiting

Immunomodulatory Treatment with Prednisone, Azithromycin and Hydroxychloroquine in Patients with Surfactant‑Related Gene Mutation Interstitial Lung Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azithromycin
  • Sponsor:Assistance Publique Hopitaux De Paris

Chronic obstructive pulmonary disease

Not yet recruiting

Study of dupilumab added to standard care in adults hospitalized for COPD exacerbation to reduce readmissions, emergency visits, and death

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Conjunctivitis allergic+1

Not yet recruiting

Diagnostic Accuracy of Parietaria judaica Pollen Extract (SPT‑RX) in a Skin Prick Test Drug Combination for Adults with Allergic Rhinitis and Controlled Mild Asthma

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Betula Pendula Pollen Extract
  • Sponsor:ROXALL Medizin GmbH

Hypersensitivity pneumonitis

Not yet recruiting

Efficacy of Prednisolone Metasulfobenzoate Sodium vs Placebo in Adults with Fibrotic Hypersensitivity Pneumonitis: A Randomized Controlled Trial

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone Metasulfobenzoate Sodium
  • Sponsor:Assistance Publique Hopitaux De Paris

Adenocarcinoma gastric+3

Not yet recruiting

Study of immune response and biomarkers in patients with metastatic solid tumors treated with BMS-986340 and nivolumab

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986340
  • Sponsor:Humanitas Mirasole S.p.A.

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin174 clinical trialsPembrolizumab149 clinical trialsCisplatin132 clinical trialsPemetrexed112 clinical trialsPaclitaxel83 clinical trialsDurvalumab71 clinical trialsAtezolizumab53 clinical trialsNivolumab50 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.